Femme et Homme
- | Pays :
- Russian Federation
- Canada
- United States
- Les 6 autres...
- | Organes : -
- | Spécialités : -
Extrait
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.
Critère d'inclusion
- Acute Gouty Arthritis Flares